drugset
drugset / Trial / NCT00421707

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707 ↗

Phase 2 Completed 133 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008

Timeline

Start
2006-10-14
Primary completion
2008-06-25
Completion
2008-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject EMICERFONT Small molecule — —

Indications

irritable bowel syndrome